craniotomy
Conditions
Interventions
Fosaprepitant group (group F) : drug 1 (= fosaprepitant 150mg + saline 100ml) and dexamethason 10mg is intravenously administered after induction of anesthesia and drug 2 (saline 2ml) is intravenous
Sponsors
Department of anesthesiology, Nara medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients from 20 years old to 80 years old undergoing craniotomy
Exclusion criteria
Exclusion criteria: 1. high risk patient (ASA risk 4 and above) 2. patient with low level of consciousness (Japan Coma Scale 2 and above) Patient with preoperative lowered consciousness is excluded before registration and patient with postoperative lowered consciousness is excluded when it is detected. Patient who exits from operating room with tracheal intubation is also excluded from analysis. 3. patient with nausea or vomiting before surgery 4. antiemetic-taken patient within 24 hours before surgery 5. patient with motions disease 6. patient with highly impaired liver function and renal function 7. patient with morbid obesity (BMI more than 35) 8. patient with allergy to fosaprepitant, aprepitant, droperidol, dexamethasone, propofol, or rocronium 9. patient with cognitive dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative accumulative incidence of PONV within 72 hours after surgery | — |
Countries
Japan
Contacts
Public ContactJun Atsuta
Nara medical university Department of anesthesiology
Outcome results
None listed